Research article Special Issues

An SIS epidemic model with time delay and stochastic perturbation on heterogeneous networks

  • Received: 01 July 2021 Accepted: 04 August 2021 Published: 13 August 2021
  • An SIS epidemic model with time delay and stochastic perturbation on scale-free networks is established in this paper. And we derive sufficient conditions guaranteeing extinction and persistence of epidemics, respectively, which are related to the basic reproduction number R0 of the corresponding deterministic model. When R0<1, almost surely exponential extinction and p-th moment exponential extinction of epidemics are proved by Razumikhin-Mao Theorem. Whereas, when R0>1, the system is persistent in the mean under sufficiently weak noise intensities, which indicates that the disease will prevail. Finally, the main results are demonstrated by numerical simulations.

    Citation: Meici Sun, Qiming Liu. An SIS epidemic model with time delay and stochastic perturbation on heterogeneous networks[J]. Mathematical Biosciences and Engineering, 2021, 18(5): 6790-6805. doi: 10.3934/mbe.2021337

    Related Papers:

    [1] Ian M Rowbotham, Franco F Orsucci, Mohamed F Mansour, Samuel R Chamberlain, Haroon Y Raja . Relevance of Brain-derived Neurotrophic Factor Levels in Schizophrenia: A Systematic Review and Meta-Analysis. AIMS Neuroscience, 2015, 2(4): 280-293. doi: 10.3934/Neuroscience.2015.4.280
    [2] Che Aishah Nazariah Ismail, Rahimah Zakaria, Khairunnuur Fairuz Azman, Nazlahshaniza Shafin, Noor Azlina Abu Bakar . Brain-derived neurotrophic factor (BDNF) in chronic pain research: A decade of bibliometric analysis and network visualization. AIMS Neuroscience, 2024, 11(1): 1-24. doi: 10.3934/Neuroscience.2024001
    [3] Natalie Ceballos, Shobhit Sharma . Risk and Resilience: The Role of Brain-derived Neurotrophic Factor in Alcohol Use Disorder. AIMS Neuroscience, 2016, 3(4): 398-432. doi: 10.3934/Neuroscience.2016.4.398
    [4] Yinghua Zhang, Xinyue Wei, Wenhao Zhang, Feng Jin, Wenbo Cao, Mingjin Yue, Saijun Mo . The BDNF Val66Met polymorphism serves as a potential marker of body weight in patients with psychiatric disorders. AIMS Neuroscience, 2024, 11(2): 188-202. doi: 10.3934/Neuroscience.2024012
    [5] Gigi Tevzadze, Tamar Barbakadze, Elisabed Kvergelidze, Elene Zhuravliova, Lali Shanshiashvili, David Mikeladze . Gut neurotoxin p-cresol induces brain-derived neurotrophic factor secretion and increases the expression of neurofilament subunits in PC-12 cells. AIMS Neuroscience, 2022, 9(1): 12-23. doi: 10.3934/Neuroscience.2022002
    [6] Zarina Greenberg, Hayley Ramshaw, Quenten Schwarz . Time Windows of Interneuron Development: Implications to Our Understanding of the Aetiology and Treatment of Schizophrenia. AIMS Neuroscience, 2015, 2(4): 294-321. doi: 10.3934/Neuroscience.2015.4.294
    [7] Priscila Centeno Crespo, Leo Anderson Meira Martins, Otávio Garcia Martins, Clara Camacho Dos Reis, Ricardo Netto Goulart, Andressa de Souza, Liciane Fernandes Medeiros, Vanessa Leal Scarabelot, Giovana Duzzo Gamaro, Sabrina Pereira Silva, Marcos Roberto de Oliveira, Iraci Lucena da Silva Torres, Izabel Cristina Custódio de Souza . Short-term effectiveness of transcranial direct current stimulation in the nociceptive behavior of neuropathic pain rats in development. AIMS Neuroscience, 2023, 10(4): 433-446. doi: 10.3934/Neuroscience.2023032
    [8] Baptiste Lerosier, Gregory Simon, Sylvain Takerkart, Guillaume Auzias, Sonia Dollfus . Sulcal pits of the superior temporal sulcus in schizophrenia patients with auditory verbal hallucinations. AIMS Neuroscience, 2024, 11(1): 25-38. doi: 10.3934/Neuroscience.2024002
    [9] Carolyn E. Jones, Miranda M. Lim . Phasic Sleep Events Shape Cognitive Function after Traumatic Brain Injury: Implications for the Study of Sleep in Neurodevelopmental Disorders. AIMS Neuroscience, 2016, 3(2): 232-236. doi: 10.3934/Neuroscience.2016.2.232
    [10] Chacchu Bhattarai, Phanindra Prasad Poudel, Arnab Ghosh, Sneha Guruprasad Kalthur . The RET gene encodes RET protein, which triggers intracellular signaling pathways for enteric neurogenesis, and RET mutation results in Hirschsprung's disease. AIMS Neuroscience, 2022, 9(1): 128-149. doi: 10.3934/Neuroscience.2022008
  • An SIS epidemic model with time delay and stochastic perturbation on scale-free networks is established in this paper. And we derive sufficient conditions guaranteeing extinction and persistence of epidemics, respectively, which are related to the basic reproduction number R0 of the corresponding deterministic model. When R0<1, almost surely exponential extinction and p-th moment exponential extinction of epidemics are proved by Razumikhin-Mao Theorem. Whereas, when R0>1, the system is persistent in the mean under sufficiently weak noise intensities, which indicates that the disease will prevail. Finally, the main results are demonstrated by numerical simulations.



    Schizophrenia is a complex psychiatric disorder with a prevalence rate of about 1 in 222 people (0.45%) among adults [1]. It affects people all over the world because of its long-term course, severe personality changes, and neurocognitive deficit such as working memory, attention and executive function that reduces the quality of life and causes a high percentage of patient disability [2],[3]. A neurocognitive deficit occurs in the early stage of schizophrenia and usually persists at all stages of the disorder [4]. It is recognised as a separate domain alongside positive and negative problems in several schizophrenia concepts, and it is an essential predictor of the disease's unfavourable prognosis and the development of persistent social dysfunction [5].

    Multiple lines of evidence link altered neurotransmitter systems and brain connections with clinical observations of cognitive deficits and negative symptoms to disrupted neuroplasticity as the aetiology of schizophrenia [6][10]. One of the processes that are known to mediate neuroplasticity in the central nervous system is changes in neurotrophic factor activity [11],[12]. Neurotrophins such as brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF) and glial cell line-derived neurotrophic factor (GDNF) are neuronal activity regulators involved in the development and maintenance of the mature nervous system, and as such, they may also contribute to the pathophysiology of schizophrenia [13].

    Schizophrenia has become a rather wide discipline with its various research areas, which increases the number of studies every day and is one of the most researched topics in psychiatry. Earlier bibliometric studies mapped the author collaborations in schizophrenia [14] and the global scientific outputs of schizophrenia publications [15]. The former study involved 58,107 records from 2003 to 2012, downloaded from the Science Citation Index Expanded (SCI-Expanded) via the Web of Science. Based on their hierarchical clustering analysis, genetic research in schizophrenia was the main collaborative field. The latter study analysed 103,992 records also from the Web of Science database between 1975 and 2020. The authors demonstrated that some of the trend keywords that have been used in recent years include BDNF. BDNF is one of the most studied neurotrophins and is produced at the pre- and post-synaptic neurons [16]. It influences synaptic plasticity, causing significant changes in cognitive functioning, learning, and memory [17],[18]. It is also necessary for the development and maintenance of dopaminergic, GABAergic, cholinergic, and serotonergic neurons [19]. Variations in BDNF may cause changes in the brains of schizophrenia patients, such as a reduction in frontal grey matter volume and an increase in lateral ventricles and sulcal cerebrospinal fluid volume [20]. Additionally, BDNF has been investigated as a possible biomarker in cognition [21],[22] diagnosis and evaluation of schizophrenia [23]. To the best of our knowledge, this is the first article to carry out a bibliometric analysis of BDNF and schizophrenia publications. A few bibliometric analytic methodologies were used to address the following research issues.

    • What are the main subjects and themes of the research on BDNF and schizophrenia?
    • What are the important strong research areas in the field of BDNF and schizophrenia?
    • What are the research trends and changes in the authors' knowledge network related to recent literature on schizophrenia and BDNF?

    The data were retrieved on 27th April 2022 from the Scopus database. A search of the relevant literature was carried out using the Scopus database because this database includes a larger number of publications and has more citations [24],[25]. We believed that there is sufficient information available to provide a sketch of the scientific landscape, research hotspots, and other pertinent details. The following search query in the article title was used: (TITLE(schizophrenia) AND TITLE (“brain derived neurotrophic factor” OR “brain-derived neurotrophic factor” OR bdnf)). Documents other than the English language (n = 9), retracted (n = 1) and the erratum (n = 13) documents were excluded (Figure 1).

    Figure 1.  Flow diagram of the search strategy [26].

    A total of 335 documents were extracted from the Scopus database in Microsoft Excel (.xls), Research Information Systems (.ris) and Comma-Separated Values (.csv) format. The data in .ris and .csv format were analysed using Harzing's Publish or Perish [27] and VOSviewer version 1.6.17 [28] for descriptive and network analysis, respectively.

    Figure 2 depicts the annual trends in the number of publications. The publications barely reached two digits in 2005 and show an overall upward trend which peaks in 2021. The trend line shows that the number of publications increases polynomially (R2 = 0.7365).

    Figure 2.  Trends in publications related to BDNF and schizophrenia.

    Most productive authors in that discipline are individual researchers who have made significant contributions to the growth and evolution of a research field. In BDNF and schizophrenia research, Zhang XY is ranked topmost with 22 publications and 938 citations, followed by Chen DC (14 publications, 736 citations), Tan YL (10 publications, 317 citations), Soares JC (10 publications, 277 citations), and Kosten TR (9 publications, 601citations) as shown in Table 1. The most productive authors are mostly from China and two from the USA and they co-authored some of the studies.

    Table 1.  Most productive authors.
    Author's Name Affiliation Country TP NCP TC C/P C/CP h g
    Zhang, X.Y. Chinese Academy of Sciences, Beijing, China China 22 22 938 42.64 42.64 16 22
    Chen, D.C. Peking University, Beijing, China China 14 14 736 52.57 52.57 13 14
    Soares, J.C. University of Texas Health Science Center at Houston, Houston, United States USA 10 10 277 27.70 27.70 9 10
    Tan, Y.L. Peking University, Beijing, China China 10 10 317 31.70 31.70 9 10
    Kosten, T.R. Baylor College of Medicine, Houston, United States USA 9 9 601 66.78 66.78 8 9
    Pillai, A. VA Medical Center, Department of Research and Development, United States USA 9 9 362 40.22 40.22 6 9
    Xiu, M.H. Peking University, Beijing, China China 17 11 580 34.12 52.73 9 17
    Huang, T.L. Chang Gung Memorial Hospital, Genomic and Proteomic Core Laboratory, Taipei, Taiwan Taiwan 8 8 217 27.13 27.13 6 8
    Yoshimura, R. University of Occupational and Environmental Health, Japan, Kitakyushu, Japan Japan 8 7 110 13.75 15.71 6 8
    Gama, C.S. Universidade Federal do Rio Grande do Sul, Departamento de Psiquiatria e Medicina Legal, Porto Alegre, Brazil Brazil 7 7 308 44.00 44.00 7 7
    Hori, H. Fukuoka University, Department of Psychiatry, Fukuoka, Japan Japan 7 7 110 15.71 15.71 6 7
    Nakamura, J. University of Occupational and Environmental Health, Japan Japan 7 7 163 23.29 23.29 6 7
    Weickert, C.S. University of New South Wales Faculty of Medicine, School of Psychiatry, Kensington, Australia Australia 7 7 1191 170.14 170.14 6 7
    Zhang, X.Y. Institute of Psychology Chinese Academy of Sciences, Beijing, China China 7 5 27 2.45 5.40 3 5

    Source: created by the author based on Scopus and Harzing's Publish and Perish data

     | Show Table
    DownLoad: CSV

    Table 2 listed the most cited publications on BDNF and schizophrenia in terms of the total number of citations. The journal Molecular Psychiatry published half of the papers listed in Table 2. Angelucci et al. [17] published in Molecular Psychiatry in 2005 was the topmost cited, with 445 citations. The second topmost cited article was an original article involving 57 post-mortem brains of patients with schizophrenia that was also published in Molecular Psychiatry in 2003 [29]. The third topmost cited article was a meta-analysis of 39 case-control studies encompassing psychiatric phenotypes: eating disorders, substance-related disorders, mood disorders, and schizophrenia, among others. This article was published in Biological Psychiatry in 2007 [30].

    Table 2.  Most cited articles.
    No. Authors Title Source Year TC C/Y References
    1 Angelucci F, Brenè S, Mathé A BDNF in schizophrenia, depression and corresponding animal models Molecular Psychiatry 2005 445 26.18 [17]
    2 Weickert CS, Hyde TM, Lipska BK, Herman MM, Weinberger DR, Kleinman JE Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia Molecular Psychiatry 2003 435 22.89 [29]
    3 Gratacòs M, González JR, Mercader JM, de Cid R, Urretavizcaya M, Estivill X Brain-Derived Neurotrophic Factor Val66Met and Psychiatric Disorders: Meta-Analysis of Case-Control Studies Confirm Association to Substance-Related Disorders, Eating Disorders, and Schizophrenia Biological Psychiatry 2007 342 22.80 [30]
    4 Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ Brain-derived neurotrophic factor levels in schizophrenia: A systematic review with meta-analysis Molecular Psychiatry 2011 316 28.73 [31]
    5 Hashimoto T, Bergen SE, Nguyen QL, Xu B, Monteggia LM, Pierri JN, Sun Z, Sampson AR, Lewis DA Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia Journal of Neuroscience 2005 316 18.59 [32]
    6 Thompson Ray M, Weickert CS, Wyatt E, Webster MJ Decreased BDNF, TrkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders Journal of Psychiatry and Neuroscience 2011 248 22.55 [33]
    7 Neves-Pereira M, Cheung JK, Pasdar A, Zhang F, Breen G, Yates P, Sinclair M, Crombie C, Walker N, St Clair DM BDNF gene is a risk factor for schizophrenia in a Scottish population Molecular Psychiatry 2005 241 14.18 [34]
    8 Ho BC, Milev P, O'Leary DS, Librant A, Andreasen NC, Wassink TH Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers Archives of General Psychiatry 2006 224 14.00 [35]
    9 Vinogradov S, Fisher M, Holland C, Shelly W, Wolkowitz O, Mellon SH Is Serum Brain-Derived Neurotrophic Factor a Biomarker for Cognitive Enhancement in Schizophrenia? Biological Psychiatry 2009 168 12.92 [36]
    10 Krebs M, Guillin O, Bourdel MC, Schwartz JC, Olie JP, Poirier MF, Sokoloff P Brain-derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia Molecular Psychiatry 2000 158 7.18 [37]

    Source: created by the author based on Scopus and Harzing's Publish and Perish data

     | Show Table
    DownLoad: CSV

    In this study, VOSviewer was used to generate the keyword co-occurrence map. A total of 457 keywords were collected from our collection of 335 BDNF and schizophrenia publications. Only keywords that appeared at least three times were selected for keyword analysis. This criterion was met by 79 keywords out of 457. Our analysis indicates that the keyword network has four distinct clusters as shown in Figure 3: cluster one (red, 26 keywords), cluster two (green, 21 keywords), cluster three (blue, 21 keywords) and cluster four (yellow, 11 keywords).

    Figure 3.  Co-occurrence network analysis. Data source: Scopus. Visualisation: VOSviewer.

    In this study, VOSviewer was used to generate the co-citation network map. The data was evaluated using the fractional counting approach with 10 as a minimum number of citations of a cited reference to create a co-citation network. The minimum cluster size was set at five. This criterion was met by 39 cited references out of 14144. The analysis resulted in a three-cluster network (Figure 4), the top 10 of which are listed in Table 3, while Table 4 summarizes BDNF in the schizophrenia co-citation network. The yellow cluster in the co-occurrence network analysis (Figure 3) correlated to the red cluster, which was associated with BDNF as a neurobiological marker in treatment monitoring (Figure 4). While the green and blue clusters exhibited a correlation with the blue and green clusters, respectively, these clusters were connected to the brain's BDNF distribution related to memory function and the function of BDNF polymorphism in the pathogenesis/risk of schizophrenia. The red cluster in the co-occurrence network analysis (Figure 3) was dispersed throughout all three clusters in Figure 4.

    Figure 4.  Co-citation network of a cited reference. Data source: Scopus. Visualisation: VOSviewer.
    Table 3.  Top 10 with the highest link strength, citations, and the number of links in the BDNF and schizophrenia field.
    TLS Citations Links Reference
    68 77 37 [38]
    45 51 37 [29]
    38 40 36 [39]
    37 46 31 [40]
    32 32 37 [41]
    31 42 30 [31]
    30 30 38 [42]
    29 31 29 [43]
    27 29 34 [44]
    24 26 31 [45]

    TLS: total link strength

    Source: created by the author based on the VOSviewer analysis

     | Show Table
    DownLoad: CSV
    Table 4.  Summary of BDNF and schizophrenia co-citation network (Clusters 1–3).
    Cluster Representative authors Content Core theoretical backgrounds
    1 (Red, 15 articles) Pirildar et al. 2004 [46]; Tan et al. 2005 [42]; Buckley et al. 2007 [47]; Gama et al. 2007 [48]; Grillo et al. 2007 [45]; Jindal et al. 2010 [49]; Buckley et al. 2011 [50]; Green et al. 2011 [31] BDNF as a neurobiological marker Treatment monitoring
    2 (Green, 15 articles) Thoenen 1995 [51]; Altar et al. 1997 [52]; Takahashi et al. 2000 [39]; Durany et al. 2001 [41]; Guillin et al. 2001 [53]; Lipska et al. 2001 [54]; Weickert, et al. 2003 [29]; Hashimoto et al. 2005 [32] Distribution of BDNF in the brain Role in memory
    3 (Blue, 9 articles) Egan et al. 2003 [38]; Hong et al. 2003 [20]; Neves-Pereira et al. 2005 [34]; Tan et al. 2005 [55] Role of BDNF polymorphism Pathogenesis/risk of schizophrenia

    Source: created by the author based on the VOSviewer analysis

     | Show Table
    DownLoad: CSV

    In this study, VOSviewer was used to generate the bibliographical coupling network map. The BDNF and schizophrenia publications from 2018 to 2022 were evaluated by bibliographic coupling using the full counting approach. A document with five as a minimum number of citations was selected to create a bibliographic coupling network. This criterion was met by 38 documents out of 345. Bibliographic coupling resulted in a five-cluster network (Figure 5), the details of which are listed in Table 5. The network's total link strength is 2570, meaning, the 37 document-based bibliographic networks appeared 2570 times jointly. There are a total of five clusters. The first cluster (red) shows the highest degree of coherence within the cluster while the fifth cluster (purple) shows the lowest degree of coherence within the cluster.

    Figure 5.  Bibliographic coupling network of the field by documents. Data source: Scopus. Visualisation: VOSviewer.
    Table 5.  Bibliographic coupling network of the field by documents.
    Cluster Pioneers Title of work Citations TLS Theme of the cluster
    1 (11) Yang et al. 2019 [56] Sex difference in the association of body mass index and BDNF levels in Chinese patients with chronic schizophrenia 20 94 Factors affecting BDNF level or dysfunction
    Wynn et al. 2018 [57] The effects of curcumin on brain-derived neurotrophic factor and cognition in schizophrenia: a randomized controlled study 17 15
    Pawełczyk et al. 2019 [58] An increase in plasma brain-derived neurotrophic factor levels is related to n-3 polyunsaturated fatty acid efficacy in first episode schizophrenia: secondary outcome analysis of the offer randomized clinical trial 13 91
    Penadés et al. 2018 [59] BDNF as a marker of response to cognitive remediation in patients with schizophrenia: a randomized and controlled trial 12 53
    Gökçe et al. 2019 [60] Effect of exercise on major depressive disorder and schizophrenia: a BDNF focused approach 11 85
    Binford et al. 2018 [61] Serum BDNF is positively associated with negative symptoms in older adults with schizophrenia 9 71
    Skibinska et al. 2018 [62] val66met functional polymorphism and serum protein level of brain-derived neurotrophic factor (BDNF) in acute episode of schizophrenia and depression 8 102
    Atake et al. 2018 [63] The impact of aging, psychotic symptoms, medication, and brain-derived neurotrophic factor on cognitive impairment in Japanese chronic schizophrenia patients 7 70
    Faatehi et al. 2019 [64] Early enriched environment prevents cognitive impairment in an animal model of schizophrenia induced by mk-801: role of hippocampal BDNF 7 24
    Guo et al. 2020 [65] ω-3pufas improve cognitive impairments through ser133 phosphorylation of creb upregulating BDNF/trkb signal in schizophrenia 6 28
    Weickert et al. 2019 [66] Increased plasma brain-derived neurotrophic factor (BDNF) levels in females with schizophrenia 5 104

    2 (10) Mohammadi et al. 2018 [67] Dysfunction in brain-derived neurotrophic factor signaling pathway and susceptibility to schizophrenia, Parkinson's and Alzheimer's diseases 49 88 BDNF dysfunction
    Zhang et al. 2018 [68] Brain-derived neurotrophic factor as a biomarker for cognitive recovery in acute schizophrenia: 12-week results 30 85
    Fang et al. 2019 [69] Depressive symptoms in schizophrenia patients: a possible relationship between sirt1 and BDNF 17 24
    Zhang et al. 2018 [70] Interaction between BDNF and TNF-α genes in schizophrenia 16 78
    Han et al. 2020 [71] BDNF as a pharmacogenetic target for antipsychotic treatment of schizophrenia 12 87
    Xia et al. 2018 [72] Suicide attempt, clinical correlates, and BDNF val66met polymorphism in chronic patients with schizophrenia 8 86
    Schweiger et al. 2019 [73] Effects of BDNF val 66 met genotype and schizophrenia familial risk on a neural functional network for cognitive control in humans 7 55
    Huang et al. 2019 [74] BDNF val66met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizoaffective disorder patients: a meta-analysis 7 49
    Kim et al. 2018 [75] 196g/a of the brain-derived neurotrophic factor gene polymorphisms predicts suicidal behavior in schizophrenia patients 7 48
    Shoshina et al. 2021 [76] Visual processing and BDNF levels in first-episode schizophrenia 5 63

    3 (7) Man et al. 2018 [77] Cognitive impairments and low BDNF serum levels in first-episode drug-naive patients with schizophrenia 34 163 BDNF as a neurobiological marker for cognition in schizophrenia
    Yang et al. 2019 [78] Brain-derived neurotrophic factor is associated with cognitive impairments in first-episode and chronic schizophrenia 27 136
    Heitz et al. 2019 [79] Plasma and serum brain-derived neurotrophic factor (BDNF) levels and their association with neurocognition in at-risk mental state, first episode psychosis and chronic schizophrenia patients 22 149
    Pillai et al. 2018 [80] Predicting relapse in schizophrenia: is BDNF a plausible biological marker? 11 67
    Wu et al. 2018 [81] Effects of risperidone and paliperidone on brain-derived neurotrophic factor and n400 in first-episode schizophrenia 7 18
    Nieto et al. 2021 [22] BDNF as a biomarker of cognition in schizophrenia/psychosis: an updated review 5 99
    Tang et al. 2019 [82] Serum BDNF and GDNF in Chinese male patients with deficit schizophrenia and their relationships with neurocognitive dysfunction 5 94

    4 (6) Wei et al. 2020 [83] Interaction of oxidative stress and BDNF on executive dysfunction in patients with chronic schizophrenia 25 88 BDNF as a neurobiological marker for cognition in schizophrenia
    Ben-Azu et al. 2018 [84] Involvement of gabaergic, BDNF and Nox-2 mechanisms in the prevention and reversal of ketamine-induced schizophrenia-like behavior by morin in mice 19 13
    Xiu et al. 2019 [85] Interaction of BDNF and cytokines in executive dysfunction in patients with chronic schizophrenia 13 48
    Ahmed et al. 2018 [86] Vinpocetine halts ketamine-induced schizophrenia-like deficits in rats: impact on BDNF and GSK-3β/β-catenin pathway 8 28
    Wu et al. 2020 [87] BDNF serum levels and cognitive improvement in drug-naive first episode patients with schizophrenia: a prospective 12-week longitudinal study 5 66
    Xu et al. 2019 [88] Applying vinpocetine to reverse synaptic ultrastructure by regulating BDNF-related psd-95 in alleviating schizophrenia-like deficits in rat 5 18

    5 (3) Di Carlo et al. 2020 [89] Brain-derived neurotrophic factor and schizophrenia 19 117 Non specific
    Mizui et al. 2019 [90] Cerebrospinal fluid BDNF pro-peptide levels in major depressive disorder and schizophrenia 17 64
    Hou et al. 2018 [91] Schizophrenia-associated rs4702 g allele-specific downregulation of furin expression by mir-338-3p reduces BDNF production 17 2

    TLS: total link strength

    Source: created by the author based on the VOSviewer analysis

     | Show Table
    DownLoad: CSV

    The BDNF and schizophrenia publications show an overall upward trend that peaks in 2021. The first article on the topic of BDNF in schizophrenia was published in the American Journal of Medical Genetics in 1997. This was the first scientific work indexed in the Scopus database to deal with the BDNF polymorphism as the possible candidate gene for schizophrenia [92]. This study was conducted on 60 unrelated Japanese schizophrenic patients and reported no evidence for the association between polymorphism and schizophrenia. Other studies included the Japanese population [93], the relationship between brain morphology and BDNF [94], SNPs within BDNF [95], and the effects of aripiprazole on BDNF [96]. The study also suggested further studies to be conducted on a larger number of subjects including other ethnicities. Case-control studies were later conducted on 130 French Caucasian schizophrenic patients and healthy volunteers [97] and 265 familial schizophrenic and healthy subjects in Irish families [98]. Both studies found no significant differences in allele frequencies or genotype distribution between patients and controls [97],[98]. Some of the later studies were also conducted in different populations such as Scottish [34], Dutch [99], Chinese [100][106], Asian [107], Russian [108], Egyptian [109],[110], Polish [111][113], Malay [114], and Turkish [115],[116]. These highlight the diversity in genetic research and the importance of studying BDNF and its related receptor genes in different populations.

    The most prolific authors in a field can assist to identify scholars who have made significant contributions to the field's growth and progress. Most of the prolific authors are mostly from China and two are from the USA and they co-authored some of the studies. Their studies addressed a variety of themes which were related to BDNF and smoking [117][119], antipsychotic drugs [120],[121], symptoms of schizophrenia [121],[122], risk of schizophrenia [103], and cognition [22],[57],[79].

    Most influential works are the most cited publications that have shaped the knowledge structure of a domain in that discipline. A review article by Angelucci et al. [17] published in Molecular Psychiatry in 2005 was the topmost cited, with a total of 445 citations. This review article described altered BDNF in schizophrenia, depression and animal models, as well as the effects of antipsychotic and antidepressive treatments on the expression of BDNF. The hypothesis was related to the malfunction of neurotrophic factors, which include BDNF, a mediator involved in neuronal survival and plasticity of dopaminergic, cholinergic, and serotonergic neurons in the central nervous system [17]. One of the animal models displaying structural brain deficits and supports the hypothesis that BDNF is implicated in the pathophysiology of schizophrenia was obtained by administering a single injection of methylazoxymethanol acetate (MAM) [123]. The second topmost cited article was an original article that was also published in Molecular Psychiatry in 2003. The study involved 57 post-mortem brains of patients with schizophrenia. They found a reduction in BDNF production and availability in the dorsolateral prefrontal cortex (DLPFC) of schizophrenics, and suggest that intrinsic cortical neurons, afferent neurons, and target neurons may receive less trophic support [29]. The third topmost cited article was published in Biological Psychiatry in 2007. The article was a meta-analysis of 39 case-control studies encompassing psychiatric phenotypes: eating disorders, substance-related disorders, mood disorders, and schizophrenia, among others. The study confirms the association of Val66Met with substance-related disorders, eating disorders, and schizophrenia [30]. The original and review articles about BDNF and its TrkB receptor [32],[33], BDNF polymorphism [124] and its role as cognitive markers [22],[36], and therapeutic response in patients with schizophrenia [37] make up the remaining top cited documents.

    Keyword co-occurrence networks aid in the identification of relevant keywords used in publications within a knowledge domain and provide information on the domain's core research themes [125]. Our analysis resulted in four distinct clusters. The red cluster is the largest cluster with common keywords such as BDNF, neurotrophic factor, cognition, neuroplasticity, neurodevelopmental, and first-episode schizophrenia. These keywords indicate that the red cluster has publications that focus on the BDNF role related to the pathogenesis of schizophrenia. The research focused on the neurobiology of schizophrenia has emphasized the relevance of neurodevelopmental and neurotoxicity-related elements in the pathogenesis of this disease as reflected by the relevant keywords such as neuroplasticity, neurodevelopmental, and neuroprotection. Another important inference in this cluster is related to biomarkers for schizophrenia that include peripheral (BDNF/neurotrophic factor, matrix metallopeptidase 9 (MMP-9), cytokine, oxidative stress) and neuroimaging (magnetic resonance imaging (MRI), cortical thickness) biomarkers.

    The green (second) and blue (third) clusters are the second largest cluster, each with 21 keywords. Association, polymorphism, genetic, psychosis, age of onset, genetic polymorphism and smoking are the common keywords in the green cluster. These keywords indicate that the green cluster has publications that focus on BDNF polymorphism associated with smoking/nicotine in schizophrenia as well as functional polymorphisms of other genes such as dopamine, drd3 and COMT. While the common keywords in the blue cluster include schizophrenia, antipsychotic, cognitive function, cognitive deficit, depression, risperidone, olanzapine, and positive and negative syndrome scale (PANSS). This cluster has publications that focus on the role of BDNF in monitoring the effects of antipsychotics on PANSS and cognition.

    The yellow cluster is the smallest cluster and the main keywords are BDNF val66met, meta-analysis, bipolar disorders, biomarker, single nucleotide polymorphism (SNP), DNA methylation, prefrontal, and epigenetic. These keywords indicate that the yellow cluster has publications that focus on the role of BDNF polymorphism as a biomarker in the pathogenesis of schizophrenia and bipolar disorders. Another important inference from this analysis is that this cluster employed meta-analysis while studying the BDNF polymorphism as a biomarker.

    Co-citation networks, which are commonly utilised in bibliometric network analysis, concentrate on the interactions or linkages between two publications [126]. When two papers are cited in a third paper, the former is said to as ‘co-cited.’ As more publications cite both of them, the co-citation relationship between them becomes stronger [127] and indicates strong study topics in a knowledge domain [128]. The first cluster (red) consists of 15 documents and six of which are listed as the top 10 with the highest total link strength (TLS) [31],[40],[42][45]. This cluster focuses on BDNF as a neurobiological marker and was used for diagnosis and treatment monitoring [31],[42],[45][50]. In terms of the time frame, this cluster has the widest range, comprises of documents published from 1987 to 2012.

    Cluster 2 (green) has the same size as cluster 1 (red) and three documents are listed in the top 10 with the highest TLS [29],[39],[41]. This cluster consists of 15 documents that discuss the distribution of BDNF in the brain and its role in memory [29],[32],[39],[41],[51][54]. In terms of the publication date, this cluster includes works from 1991 to 2003. Finally, cluster 3 (blue) has the lowest number of documents and only one of the documents is listed in the top 10 with the highest TLS [38]. This cluster discusses mainly the role of BDNF polymorphism in the pathogenesis and risk of schizophrenia [20],[34],[38],[55]. It includes documents from 2001 to 2005.

    Another widely used method for analysing and visualising knowledge networks in a topic is bibliographic coupling [129]. Two publications are bibliographically connected if they both quote the same third publication, i.e., they have the same reference list, with a higher commonality of publication suggesting a stronger coupling [129],[130]. It is a potential method of examining recent trends and changes in an author's knowledge network over time [128]. There are a total of five clusters. The first cluster shows the highest degree of coherence within the cluster. In the cluster (in red in Fig. 4), “Sex difference in the association of body mass index and BDNF levels in Chinese patients with chronic schizophrenia”, the most important article was the one by Yang et al. [56], which focused on the needs to consider sex when assessing the relationship between BDNF and metabolic syndromes in schizophrenia. Atake et al. [63] commented on the impact of ageing, psychotic symptoms, medication, and brain-derived neurotrophic factor on cognitive impairment in Japanese chronic schizophrenia patients. Both articles discussed the changes in BDNF levels due to different factors in two different ethics i.e. Chinese and Japanese schizophrenia patients. Weickert et al. [66] and Skibinska et al. [62] had the highest total link strength in researching the increased plasma BDNF in females with schizophrenia, and the association between val66met functional polymorphism and serum BDNF in schizophrenia and depression, respectively.

    In the second cluster (in green in Fig. 4), the most important article was “Dysfunction in brain-derived neurotrophic factor signalling pathway and susceptibility to schizophrenia, Parkinson's and Alzheimer's diseases” by Mohammadi et al. [67]. The review paper highlighted the BDNF signalling pathway dysfunction in various brain diseases. The BDNF dysfunctions were also reported in schizophrenia and schizoaffective disorder by other studies in the same cluster [72][75].

    In the third cluster (in blue in Fig. 4), “Cognitive impairments and low BDNF serum levels in first-episode drug-naive patients with schizophrenia”, was the most important article by Man et al. [77]. In both patients and healthy controls, no significant link was identified between BDNF and neuropsychological score. The study findings imply that excessive cognitive deficits are prevalent in the early stages of schizophrenia and low BDNF levels may have a role in the aetiology of schizophrenia, although not necessarily in cognitive problems. Other articles in the same cluster also reported the role of BDNF in the cognitive function of schizophrenia patients [68],[78],[79].

    In the fourth cluster (in yellow in Fig. 4), three of the articles focused on the role of BDNF in the cognitive function of schizophrenia patients [80],[82],[84] as in the third cluster and had the highest total link strength. Two of the articles were related to ketamine-induced schizophrenia in animal models [84],[86]. While the fifth cluster (in purple in Fig. 4) is the smallest and exhibits the lowest degree of coherence within the cluster. The articles in this cluster had high total link strength except for the article by Hou et al. [91]. The article by Hou is related to the regulation of BDNF production by microRNAs (miRNAs).

    Research on schizophrenia and BDNF has advanced significantly, particularly among experts connected to China and the USA. The main themes and strong research areas of BDNF in schizophrenia include its role as a neurobiological marker (pathogenesis, treatment monitoring, and risk factors), and cognition in schizophrenia. Recent years have seen an increase in interest in research on pertinent topics, such as factors that alter BDNF levels or are linked to BDNF dysfunction in schizophrenia, cognition in schizophrenia, and animal models of the disease. Future studies should look into the novel potential roles of BDNF in schizophrenia including regulation of inflammation, modulation of mitochondria function, epigenetic regulation, and regulation of neural oscillations.



    [1] A. L. Barabási, R. Alber, Emergence of scaling in random networks, Science, 286 (1999), 509–512. doi: 10.1126/science.286.5439.509
    [2] M. Barthelemy, A. Barrat, R. Pastor-Satorras, A. Vespignani, Dynamical patterns of epidemic outbreaks in complex heterogeneous networks, J. Theor. Biol., 235 (2004), 275–288.
    [3] T. Zhou, J. Liu, W. Bai, G. Chen, B. wang, Behaviors of susceptible-infected epidemics on scale-free networks with identical infectivity, Phys. Rev. E, 74 (2006), 056109. doi: 10.1103/PhysRevE.74.056109
    [4] R. Pastor-Satorras, A. Vespignani, Epidemic spreading in scale-free networks, Phys. Rev. Lett., 86 (2001), 3200–3203. doi: 10.1103/PhysRevLett.86.3200
    [5] R. Pastor-Satorras, A. Vespignani, Epidemic dynamics and endemic states in complex networks, Phys. Rev. E, 63 (2001), 066117. doi: 10.1103/PhysRevE.63.066117
    [6] Y. Moreno, R. Pastor-Satorras, A. Vespignanil, Epidemic outbreaks in complex heterogeneous networks, Eur. Phys. J. B, 26 (2002), 521–529.
    [7] K. Li, G. Zhu, Z. Ma, L. Chen, Dynamic stability of an SIQS epidemic network and its optimal control, Commun. Nonlinear Sci. Numer. Simul., 66 (2019), 84–95. doi: 10.1016/j.cnsns.2018.06.020
    [8] J. Liu, T. Zhang, Epidemic spreading of an SEIRS model in scale-free networks, Commun. Nonlinear Sci. Numer. Simul., 16 (2011), 3375–3384. doi: 10.1016/j.cnsns.2010.11.019
    [9] T. Li, Y. Wang, Z. Guan, Spreading dynamics of a SIQRS epidemic model on scale-free networks, Commun. Nonlinear Sci. Numer. Simul., 19 (2014), 686–692. doi: 10.1016/j.cnsns.2013.07.010
    [10] L. Wang, G. Dai, Global stability of virus spreading in complex heterogeneous networks, SIAM J. Appl. Math., 68 (2008), 1495–1502. doi: 10.1137/070694582
    [11] A. d'Onofrio, A note on global behavior of the network-based SIS epidemic model, Nonlinear Anal.: Real World Appl., 9 (2008), 1567–1572. doi: 10.1016/j.nonrwa.2007.04.001
    [12] Q. Liu, C. Deng, M. Sun, The analysis of an epidemic model with time delay on scale-free networks, Physica A, 410 (2014), 79–87. doi: 10.1016/j.physa.2014.05.010
    [13] Q. Liu, M. Sun, Dynamics of epidemic spreading model with distributed delay on heterogeneous network, J. Biol. Syst., 25 (2017), 173–183. doi: 10.1142/S0218339017500097
    [14] H. Kang, Y. Lou, G. Chen, S. Chu, X. Fu, Epidemic spreading and global stability of a new SIS model with delay on heterogenous network, J. Biol. Syst., 23 (2015), 577–595.
    [15] H. Kang, X. Fu, Epidemic spreading and global stability of an SIS model with an infective vector on complex networks, Commun. Nonlinear Sci. Numer. Simul., 27 (2015), 30–39. doi: 10.1016/j.cnsns.2015.02.018
    [16] S. Bonaccorsi, S. Ottaviano, Epidemics on networks with heterogeneous population and stochastic infection rates, Math. Biosci., 279 (2016), 43–52. doi: 10.1016/j.mbs.2016.07.002
    [17] A. Krause, L. Kurowski, K. Yawar, R. A. Van Gorder, Stochastic epidemic metapopulation models on networks: sis dynamics and control strategies, J. Theor. Biol., 449 (2018), 35–52. doi: 10.1016/j.jtbi.2018.04.023
    [18] H. Yang, Z. Jin, Stochastic SIS epidemic model on network with Lévy noise, Stoch. Anal. Appl., 2021, DOI: 10.1080/07362994.2021.1930051.
    [19] C. Li, C. Tsai, S. Yang, Analysis of epidemic spreading of an SIRS model in complex heterogeneous networks, Commun. Nonlinear Sci. Numer. Simul., 19 (2014), 1042–1054. doi: 10.1016/j.cnsns.2013.08.033
    [20] G. Zhu, X. Fu, G. Chen, Global attractivity of a network-based epidemics SIS model with nonlinear infectivity, Commun. Nonlinear Sci. Numer. Simul., 17 (2012), 2588–2594. doi: 10.1016/j.cnsns.2011.08.039
    [21] R. Olinky, L. Olinky, Unexpected epidemic threshold in heterogeneous networks: the role of disease transmission, Phys. Rev. E, 70 (2004), 030902. doi: 10.1103/PhysRevE.70.030902
    [22] Q. Luo, X. Mao, Stochastic population dynamics under regime switching, J. Math. Anal. Appl., 334 (2007), 69–84. doi: 10.1016/j.jmaa.2006.12.032
    [23] A. Gray, D. Greenhalgh, L. Hu, X. Mao, J. Pan, A stochastic differential equation SIS epidemic model, SIAM J. Appl. Math., 71 (2011), 876–902. doi: 10.1137/10081856X
    [24] L. Arnold, Stochastic Differential Equations: Theory and Applications, Wiley, New York, 1974.
    [25] X. Mao, Stochastic Differential Equations and Applications, 2nd edition, Woodhead Publishing, Cambridge, 2007.
    [26] C. Ji, D. Jiang, N. Shi, Multigroup SIR epidemic model with stochastic perturbation, Physica A, 390 (2011), 1747–1762. doi: 10.1016/j.physa.2010.12.042
    [27] H. Zhang, X. Fu, Spreading of epidemics on scale-free networks with nonlinear infectivity, Nonlinear Anal., 70 (2009), 3273–3278. doi: 10.1016/j.na.2008.04.031
    [28] D. J. Higham, An algorithmic introduction to numerical simulation of stochastic differential equations, SIAM Rev., 43 (2001), 525–546. doi: 10.1137/S0036144500378302
    [29] J. R. C. Piqueira, V. O. Araujo, A modified epidemiological model for computer viruses, Appl. Math. Comput., 213 (2009), 355–360.
    [30] J. R. C. Piqueira, M. A. M. Cabrera, C. M. Batistela, Malware propagation in clustered computer networks, Physica A, 573 (2021), 125958. doi: 10.1016/j.physa.2021.125958
  • This article has been cited by:

    1. Anton Shkundin, Angelos Halaris, Associations of BDNF/BDNF-AS SNPs with Depression, Schizophrenia, and Bipolar Disorder, 2023, 13, 2075-4426, 1395, 10.3390/jpm13091395
    2. Martin Gredicak, Matea Nikolac Perkovic, Gordana Nedic Erjavec, Suzana Uzun, Oliver Kozumplik, Dubravka Svob Strac, Nela Pivac, Association between reduced plasma BDNF concentration and MMSE scores in both chronic schizophrenia and mild cognitive impairment, 2024, 134, 02785846, 111086, 10.1016/j.pnpbp.2024.111086
    3. Anna Maria Szota, Beata Kowalewska, Małgorzata Ćwiklińska-Jurkowska, Wiktor Dróżdż, The Influence of Electroconvulsive Therapy (ECT) on Brain-Derived Neurotrophic Factor (BDNF) Plasma Level in Patients with Schizophrenia—A Systematic Review and Meta-Analysis, 2023, 12, 2077-0383, 5728, 10.3390/jcm12175728
    4. Nezha Bouhaddou, Meryem Mabrouk, Farah Atifi, Abdelhakim Bouyahya, Younes Zaid, The link between BDNF and platelets in neurological disorders, 2024, 10, 24058440, e39278, 10.1016/j.heliyon.2024.e39278
    5. Miquel Bioque, Vicent Llorca-Bofí, Karina S MacDowell, Sílvia Amoretti, Gisela Mezquida, Manuel J Cuesta, Covadonga M Diaz-Caneja, Ángela Ibáñez, Rafael Segarra, Ana González-Pinto, Alexandra Roldán, Pilar A Sáiz, Anna Mané, Antonio Lobo, Albert Martínez-Pinteño, Guillermo Cano-Escalera, Esther Berrocoso, Miquel Bernardo, Impact of Relapse in BDNF Receptors Expression in Patients With a First Episode of Schizophrenia, 2025, 0586-7614, 10.1093/schbul/sbaf012
    6. Haidong Yang, Qing Tian, Lingshu Luan, Man Yang, Chuanwei Li, Xiaobin Zhang, NGF-β and BDNF levels are altered in male patients with chronic schizophrenia: effects on clinical symptoms, 2025, 25, 1471-244X, 10.1186/s12888-025-06685-8
    7. M. V. Kuzminova, E. V. Semina, Y. A. Chayka, Biomarkers of endogenous mental disorders: the role of cortisol, extracellular DNA, BDNF, and cytokines in relation to disease stage and therapy, 2025, 20746822, 245, 10.33920/med-01-2502-13
    8. Junwei Shen, Xin Li, Yinghua Zhong, Jiechun Zhang, Hongyun Qin, Fazhan Chen, Xudong Zhao, Neuroendocrine characterization into schizophrenia: norepinephrine and melatonin as promising biomarkers, 2025, 16, 1664-2392, 10.3389/fendo.2025.1551172
    9. Anastasiia S. Boiko, Irina A. Mednova, Ekaterina V. Mikhalitskaya, Diana Z. Paderina, Dmitry A. Petkun, Elena G. Kornetova, Nikolay A. Bokhan, Svetlana A. Ivanova, BDNF gene polymorphisms and BDNF serum concentration in schizophrenia patients: a pilot study, 2025, 16, 1664-0640, 10.3389/fpsyt.2025.1556079
    10. Laura Dayanara López-Rocha, Armando Ruiz-Hernández, Gustavo Martínez-Coronilla, Ana Gabriela Leija-Montoya, Mario Peña-Peña, Fausto Sánchez-Muñoz, Ulises Rieke-Campoy, Javier González-Ramírez, The Role of Long Non-Coding RNA in Anxiety Disorders: A Literature Review, 2025, 26, 1422-0067, 5042, 10.3390/ijms26115042
    11. Violeta Mancaş, Dana Galieta Mincă , Simona Corina Trifu , Biomarkers in schizophrenia – past, present and future, 2025, 66, 12200522, 69, 10.47162/RJME.66.1.06
    12. Alaa Anwar, Aya M. Mustafa, Kareem Abdou, Mostafa A. Rabie, Riham A. El-Shiekh, Ahmed M. El-Dessouki, A comprehensive review on schizophrenia: epidemiology, pathogenesis, diagnosis, conventional treatments, and proposed natural compounds used for management, 2025, 0028-1298, 10.1007/s00210-025-04351-0
  • Reader Comments
  • © 2021 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(3429) PDF downloads(198) Cited by(3)

Figures and Tables

Figures(4)

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog